By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Bristol-Myers
Squibb Co. v. Genentech, Inc. et al.
3:13-cv-02045;
filed May 3, 2013 in the Northern District of California

• Plaintiff: 
Bristol-Myers Squibb Co.
• Defendants: 
Genentech, Inc.; City of Hope

Declaratory
judgment of invalidity, unenforceability, and noninfringement of of U.S. Patent
Nos. 6,331,415 ("Methods of Immunoglobulins, Vectors, and Transformed Host
Cells for Use Therein," issued December 18, 2001) and 7,923,221 ("Methods
of Making Antibody Heavy and Light Chains Having Specificity for a Desired
Antigen," issued April 12, 2011) in conjunction with BMS's manufacture and
sale of its Erbitux® product (cetuximab, used for the treatment of head and
neck cancer and colorectral cancer; sold pursuant to an agreement with Eli
Lilly) and its Yervoy® product (ipilimumab, used for the treatment of
unresectable or metastatic melanoma).  View
the complaint here.

Genentech,
Inc. v. Rea
1:13-cv-00556;
filed May 3, 2013 in the Eastern District of Virginia

Review and
correction of the patent term adjustment calculation made by the U.S. Patent
and Trademark Office for U.S. Patent No. 8,303,955 ("Humanized Anti-CD40 Antibodies and Their Methods of Use,"
issued November 6, 2012).  View the
complaint here.